ARCHIVES

Predicant, Correlogic executives contradict scientists’ claim that firms didn’t appear to compete.

This article is from The Cancer Letter archive.

Vol. 30 No. 26 | June 25, 2004

Download PDF Visit The Full Archive

Related Articles

NCAB Review Of Cancer Control Program Finds It Has Made Substantial Progress But Has Problems

October 13, 1978

MEPACT Approved In Europe For Resectable Osteosarcoma

March 27, 2009

Deflecting Earmarks, NCI Advisors Lay Out Research Opportunities In Breast, Prostate

February 26, 1999

Funding Opportunities

March 7, 2003

Case Western Wins Renewal.

October 5, 2001

NCI Contracts: Advisors OK Renewal Of chemoprevention Contracts By DCPC

September 6, 1996